Prospective study for the effects of pancreatic enzyme replacement therapy on quality of life and nutritional assessment after pancreas resection

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0000010

Enrollment

232

Registered

2010-06-30

Start date

2008-09-08

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Drug : Norzyme Generic name : Pancreatin Dosage : 1 tab x 3/day x 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients who underwent pancreatectomy (pancreatoduodenectomy, pylorus-preserving pancreatoduodenectomy, distal pancreatectomy, spleen-preserving distal panreatectomy, subtotal pancreatectomy) - Patients who can be regulary followed-up for at least 1 year - Informed consent

Exclusion criteria

Exclusion criteria: - Noncurative resection - Recurrence or distat metastasis - Severe comorbidity (cardiovascular, pulmonary, renal, neurologic) - Other abdominal surgery which can have impact on quality of life (ex. gastrectomy, colectomy) - Patients who cannot understand the study

Design outcomes

Primary

Measure	Time frame
quality of life	—

Secondary

Measure	Time frame
Glucose intolerance;Nutritional status;Pancreatic exocrine insufficiency;Remnant pancreas atrophy	—

Countries

Korea, Republic of

Contacts

Public ContactMee Joo Kang

Seoul National University

Outcome results